552 related articles for article (PubMed ID: 19201656)
1. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
4. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
8. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
11. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions.
Carducci MA; DeWeese TL; Nelson WG; Simons JW; Sinibaldi V; Eisenberger MA
Semin Oncol; 1996 Dec; 23(6 Suppl 14):56-62. PubMed ID: 8996587
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Lin AM; Hershberg RM; Small EJ
Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
[TBL] [Abstract][Full Text] [Related]
15. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
16. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy of prostate cancer].
Schulze H; Sommerfeld HJ
Urologe A; 1993 Sep; 32(5):382-9. PubMed ID: 8212423
[TBL] [Abstract][Full Text] [Related]
20. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
